Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash & Current Investments (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Cash & Current Investments data on record, last reported at $476.9 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 32.43% year-over-year to $476.9 million; the TTM value through Sep 2025 reached $476.9 million, up 32.43%, while the annual FY2024 figure was $350.8 million, 516.93% up from the prior year.
  • Cash & Current Investments reached $476.9 million in Q3 2025 per ZBIO's latest filing, up from $273.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $476.9 million in Q3 2025 and bottomed at $37.2 million in Q1 2024.
  • Average Cash & Current Investments over 3 years is $236.0 million, with a median of $273.3 million recorded in 2025.
  • The widest YoY moves for Cash & Current Investments: up 738.83% in 2025, down 32.43% in 2025.
  • A 3-year view of Cash & Current Investments shows it stood at $56.9 million in 2023, then surged by 516.93% to $350.8 million in 2024, then surged by 35.97% to $476.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $476.9 million in Q3 2025, $273.3 million in Q2 2025, and $312.4 million in Q1 2025.